Literature DB >> 2502556

Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect.

J Leger1, R Girot, H Crosnier, M C Postel-Vinay, R Rappaport.   

Abstract

The plasma GH response to a single iv bolus dose of 2 micrograms/kg BW synthetic GHRH-(1-44)NH2 was evaluated in 13 prepubertal children with thalassemia major (mean age, 7.6 +/- 0.8 yr) with growth retardation and in 15 prepubertal children with nonendocrine short stature. All of the patients showed a significant increase in plasma GH concentration, with a mean peak of 31.4 +/- 4.5 micrograms/L at 15 min (P less than 0.001 vs. basal values; range, 18.4-65 micrograms/L) after GHRH, which was not different from that of the control group of idiopathic short stature children (40.1 +/- 3.4 micrograms/L; range, 21-65.4 micrograms/L). All but 1 of the thalassemic patients had a normal GH response to the arginine-insulin stimulation test. The mean plasma insulin-like growth factor-I level was low (0.12 +/- 0.05 U x 10(3)/L; range, less than 0.02-0.61 U x 10(3)/L). Analysis of these results as well as previously reported data indicating that older thalassemic patients have an impaired GH response indicates that there may be an age-related pituitary and/or hypothalamic dysfunction in thalassemic children. This study also confirms that the insulin-like growth factor-I decrease occurs before any alteration in GH secretion. These changes might play a role in the early growth retardation that occurs in these patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502556     DOI: 10.1210/jcem-69-2-453

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Endocrine complications of thalassemia.

Authors:  D Tiosano; Z Hochberg
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 3.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

4.  Growth hormone response following growth hormone releasing hormone injection in thalassemia major: influence of pubertal development.

Authors:  B P Leheup; M Cisternino; M Bozzola; B Dousset; P L Marradi; F Antoniazzi; L Tato; F Severi; D Sommelet; M Pierson
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

5.  Evaluation of hypothalamic-pituitary function in patients with thalassemia major.

Authors:  L Danesi; M Scacchi; M De Martin; A Dubini; P Massaro; A T Majolo; F Cavagnini; E E Polli
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 6.  Growth of children with beta-thalassemia major.

Authors:  Louis Ck Low
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

7.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

8.  Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major.

Authors:  R G Grundy; K A Woods; M O Savage; J P Evans
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

9.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.